Dr. Alireza Nami, MD

Dr. Nami practices at Joint and Muscle Medical Care in Charlotte, North Carolina.

Dr. Nami's NPI, 1851312755, was assigned on July 23, 2006. Dr. Nami holds North Carolina license 200400560.

Dr. Nami's primary practice is Joint and Muscle Medical Care, at 332 Lillington Ave, Charlotte, NC 28204 in Mecklenburg County. The practice phone is (704) 377-1216.

Dr. Nami's primary practice is Joint and Muscle Medical Care in Charlotte, North Carolina. Dr. Nami is also affiliated with Atrium Health Carolinas Medical Center. The medical group on file is Joint and Muscle Medical Care and Research Institute. Dmand AI also links Dr. Nami to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nami practices, 3 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Nami's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Nami is licensed in North Carolina.

CMS data shows 5,475 Medicare services from Dr. Nami across 22 procedure codes in 2024, for 191 Medicare patients. Medicare paid $152,989 for them. Every service was in an office.

CMS counts 191 Medicare patients who saw Dr. Nami in 2024. The largest group is 65 to 74, with 87 patients. 75% of them have arthritis, and 71% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.39, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Nami's median patient age at 64, with 79% women.

In 2024, Dr. Nami wrote 4,995 Medicare Part D claims for 480 patients. 90% of them were for generic drugs. CMS names the drug for 4,685 of them, across 54 drugs with 11 or more claims each, at $1,767,883 in total drug cost. In 2023, CMS named 4,459 claims across 60 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Nami for performance year 2024, reported as part of a group. Dr. Nami accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Nami to 3 clinical trials. Conditions studied include Lupus Erythematosus, Systemic and Connective Tissue Diseases. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Nami that name 3 trials.

CMS Open Payments shows 1,248 general payments to Dr. Nami from 51 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 45% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $13,070. It also lists 5 research payments totaling $2,138 from 2016 to 2021, naming 3 clinical trials.